We are live on ! Find out more
DRMAW icon

Dermata Therapeutics Warrant

6 hedge funds and large institutions have $506K invested in Dermata Therapeutics Warrant in 2021 Q3 according to their latest regulatory filings, with 6 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
6
Holders Change
+6
Holders Change %
% of All Funds
0.11%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
6
Increased
Reduced
Closed
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
AC
1
Armistice Capital
New York
$270K +$334K +325,000 New
WAM
2
Warberg Asset Management
Illinois
$85K +$103K +100,000 New
Hudson Bay Capital Management
3
Hudson Bay Capital Management
Connecticut
$62K +$77K +75,000 New
BFM
4
Boothbay Fund Management
New York
$54K +$12.3K +12,000 New
WVP
5
Worth Venture Partners
New Jersey
$33K +$41.2K +40,075 New
UBS Group
6
UBS Group
Switzerland
$2K +$3.08K +3,000 New

DRMAW Hedge Fund Activity: Q3 2021 in Review

6 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Dermata Therapeutics Warrant (DRMAW) for Q3 2021, worth a combined $506K.

Buyers outnumbered sellers: 6 funds opened new DRMAW positions and 0 closed out — a net gain of 6 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $334K.

  • 6 institutional investors held Dermata Therapeutics Warrant (DRMAW) as of Q3 2021, up from 0 in Q2 2021.
  • Funds reported $506K of Dermata Therapeutics Warrant stock for Q3 2021.
  • 6 funds opened new Dermata Therapeutics Warrant positions in Q3 2021 and 0 closed out, a net change of +6 holders.
  • The largest Dermata Therapeutics Warrant buyer in Q3 2021 was Armistice Capital, an estimated $334K added.

Based on aggregated 13F filings for Q3 2021.